Skip to content
Open access

HIV DNA and transcription before and after ART in natural controllers compared to noncontrollers

Aug 2026 · Journal of Virology · Vol 100 · 0 citations · 48 references
Medicine

TL;DR

It is found that natural control was associated with mechanisms that reduce levels of total HIV DNA and the HIV promoter regions to below the levels seen in ART-treated noncontrollers (NC), resulting in lower total levels of most HIV transcripts.

Abstract

ABSTRACT HIV-1 natural controllers can limit plasma HIV RNA levels in the absence of antiretroviral therapy (ART). Although controllers have less HIV DNA, it remains unclear how HIV transcription differs from noncontrollers, and whether ART further reduces HIV DNA or RNA in controllers. To address these questions, we quantified different HIV transcripts and HIV DNA regions/proviruses in longitudinal blood samples collected before ART and up to 3–5 years on suppressive ART from 10 controllers (5 “elite” and 5 viremic) and compared them to ART-suppressed noncontrollers. Compared to noncontrollers, controllers exhibited lower levels of most HIV DNA regions (but not intact proviruses) and lower total levels of initiated and completed HIV RNA, but paradoxically higher levels per provirus of initiated and 5′ elongated HIV transcripts. Controllers also showed a lower ratio of completed/elongated HIV RNA. After ART, controllers showed lower levels of multiply spliced HIV RNA and a lower ratio of multiply spliced/completed HIV RNA. These results suggest that natural controllers limit HIV infection frequency and selectively restrict HIV transcript completion and splicing. ART treatment of controllers led to further increases in CD4 counts and decreases in HIV DNA and some HIV transcripts, supporting the potential for clinical benefits in this population. IMPORTANCE Natural HIV controllers can suppress HIV-1 replication without antiretroviral therapy (ART) and serve as a model for an HIV functional cure, but the mechanisms are unclear. We found that natural control was associated with mechanisms that reduce levels of total HIV DNA and the HIV promoter regions to below the levels seen in ART-treated noncontrollers (NC), resulting in lower total levels of most HIV transcripts. When corrected for HIV DNA levels, natural controllers exhibited higher levels per provirus of short, prematurely terminated HIV transcripts but lower proportions of completed and spliced HIV transcripts. These findings suggest that the mechanisms of natural control do not only limit HIV infection frequency, but specifically limit production or increase clearance of infected cells making completed and spliced HIV transcripts. ART treatment of controllers led to further increases in CD4+ T-cell counts and decreases in HIV DNA and RNA, suggesting that ART should be offered to controllers. Natural HIV controllers can suppress HIV-1 replication without antiretroviral therapy (ART) and serve as a model for an HIV functional cure, but the mechanisms are unclear. We found that natural control was associated with mechanisms that reduce levels of total HIV DNA and the HIV promoter regions to below the levels seen in ART-treated noncontrollers (NC), resulting in lower total levels of most HIV transcripts. When corrected for HIV DNA levels, natural controllers exhibited higher levels per provirus of short, prematurely terminated HIV transcripts but lower proportions of completed and spliced HIV transcripts. These findings suggest that the mechanisms of natural control do not only limit HIV infection frequency, but specifically limit production or increase clearance of infected cells making completed and spliced HIV transcripts. ART treatment of controllers led to further increases in CD4+ T-cell counts and decreases in HIV DNA and RNA, suggesting that ART should be offered to controllers.

Read PDF

Similar papers

Open access Aug 2026

Genomic landscape of HIV-1 proviruses in ART-treated immunological non-responders

The study reveals a distinct proviral landscape in ART-treated INRs, characterized by elevated levels of intact proviral genomes, and suggests that the intact component of the reservoir may represent a clinically relevant feature of incomplete immune reconstitution.

Shengquan Tang, Yue Wang, Yanqiu Lu et al. · 0 citations
Review Aug 2026

Quiet but not silent: assessing the impact of intact and defective HIV proviral DNA in the brain.

Defective HIV proviruses make up the majority of the proviral reservoir across blood and tissue compartments and may contribute to chronic inflammation, antigen persistence, and neuropathology in ART-suppressed PWH.

Emily K Chalmers, Janna Jamal Eddine, Liam Yucel et al. · 0 citations
Open access Aug 2026

A novel biomarker signature based on circulating transfer RNA (tRNA) can detect and differentiate HIV-2 infection from HIV-1

ABSTRACT HIV-1 and HIV-2 share transmission and replication characteristics, but require clinical differentiation. HIV-2 exhibits lower viral loads and slower disease progression, and most patients remain long-term non-progressors. Differentiation is crucial for selecting appropriate viral load monitoring tests and avo...

Santanu Biswas, D. McGivern, Indira K. Hewlett et al. · 0 citations
Open access Sep 2026

A naturally occurring Tat R52W variant in brain-derived HIV attenuates transcription and may contribute to reservoir persistence

HIV-1 persistence under suppressive antiretroviral therapy (ART) remains a major barrier to eradication, yet the contribution of naturally occurring viral variation to transcriptional regulation is incompletely understood. Here, we identify an HIV-1 Tat variant (R52W) that attenuates viral transcription through the dis...

Hong-Jie Chen, Nan Jiang, Yu-Yang Tang et al. · 0 citations
Review Open access Sep 2026

HIV Proviral DNA: Clinical Applications, Drug Resistance, and the HIV Reservoir

Abstract: Antiretroviral therapy has rendered HIV a manageable chronic infection, but integrated proviral DNA within long-lived CD4+ memory T cells persists indefinitely and constitutes both a barrier to cure and an archive of the patient’s virologic history. Genotypic resistance testing performed on proviral DNA from...

Brian Harting · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.